Zaltrap Market Report 2026

Zaltrap Market Overview

• The Zaltrap market growth in the historic period has been driven by increasing colorectal cancer incidence rates, advancement of monoclonal antibody therapies • Market expansion is supported by increasing demand for personalized oncology treatments, rising investment in cancer biologics • Growth Driver: Rising Prevalence Of Colorectal Cancer Fuel Demand For The Market • North America was the largest region in 2025.

What Is Covered Under Zaltrap Market?

Zaltrap is a prescription medication used with other chemotherapy drugs to treat metastatic colorectal cancer (mCRC). It is a VEGF inhibitor that blocks VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing angiogenesis and the formation of new blood vessels that tumors require to grow and spread, thereby slowing disease progression. The main types of indication for zaltrap are metastatic colorectal cancer (mCRC) and metastatic breast cancer. Metastatic colorectal cancer (mCRC) is a late stage of colorectal cancer in which the disease has spread to distant organs, such as the liver or lungs. It comes in formulations such as injections (100 mg/4 ml, 200 mg/8 ml) and is distributed through various distribution channels, including hospitals, oncology clinics, and pharmacies. It is used by several end users, including adult patients and geriatric patients.

What Is The Zaltrap Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising investment in cancer biologics, expansion of oncology care access in emerging markets, growing focus on combination targeted therapies, continued innovation in angiogenesis inhibition. Major trends in the forecast period include increasing use of targeted anti-angiogenic therapies, growing adoption of combination chemotherapy regimens, rising focus on biomarker-driven treatment selection, expansion of oncology infusion infrastructure, enhanced monitoring of treatment outcomes.

Global Zaltrap Market Segmentation

1) By Indication: Metastatic Colorectal Cancer (mCRC), Metastatic Breast Cancer 2) By Formulation: 100 mg/4 mL, 200 mg/8 mL 3) By Distribution Channel: Hospitals, Oncology Clinics, Pharmacies 4) By End-User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Zaltrap Market?

The increasing prevalence of colorectal cancer is expected to propel the growth of the zaltrap market going forward. Colorectal cancer is a type of cancer that originates in the colon or rectum, typically beginning as benign polyps and potentially advancing if not addressed. The prevalence of colorectal cancer is rising due to factors such as an aging population, unhealthy diets, obesity and overweight, and genetic predisposition. Zaltrap is a vascular endothelial growth factor (VEGF) inhibitor that prevents the formation of new blood vessels (angiogenesis), cutting off the tumor's blood supply. This action helps slow disease progression and enhances survival outcomes in colorectal cancer patients. For instance, in July 2024, according to a report published by Bowel Cancer UK, a UK-based bowel cancer charitable organization, around 44,000 people are diagnosed with bowel cancer each year in the UK. More than 90% of these new cases (94%) are found in individuals aged 50 and older; however, bowel cancer can impact people of any age, with over 2,600 new cases diagnosed annually in those under 50. Therefore, the increasing prevalence of colorectal cancer is driving the growth of the zaltrap industry. The increasing expenditure on cancer care is set to propel the growth of the zaltrap market moving forward. Cancer care expenditure includes all costs related to the prevention, diagnosis, treatment, and follow-up care of cancer, covering both medical and non-medical expenses. Increasing expenditure on cancer care is driven by the rising incidence of cancer, advancements in medical technology and treatments, and the growing number of cancer survivors requiring long-term management. As cancer care spending increases, the focus intensifies on targeted and effective treatments, while enhanced research and clinical trials drive the development and adoption of ZALTRAP. For instance, in September 2024, according to a report published by Cancer Research UK, a UK-based charitable funder of cancer research, in the financial year 2023/24, £399 million ($414.65) was spent on cancer research, with £93 million ($96.64) allocated to research addressing all types of cancer and £84 million ($87.29) directed towards basic research to explore the fundamental biology of cancer. Therefore, the increasing expenditure on cancer care is driving the growth of the zaltrap industry. The growing aging population is significantly driving the growth of the zaltrap market in the future. An aging population is a demographic shift characterized by a growing percentage of individuals aged 60 or 65 and above within a population. The growing aging population is driven by factors such as declining fertility rates, increased life expectancy, social services, and economic structures to better support and engage this demographic. Zaltrap provides an effective treatment for metastatic colorectal cancer, which is more prevalent in the aging population. By blocking VEGF and inhibiting tumor growth, it helps improve outcomes, slow progression, and enhance the quality of life for older cancer patients. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the growing aging population is driving the growth of the zaltrap industry.

Key Players In The Global Zaltrap Market

Major companies operating in the zaltrap market are Sanofi S.A.

Regional Insights

North America was the largest region in the zaltrap market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zaltrap Market?

The zaltrap market consists of sales of single-dose vials, prefilled syringes, and lyophilized powder for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zaltrap Market Report 2026?

The zaltrap market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zaltrap industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.